Mohsen Noreldin, MD
Pulmonary Disease · Westborough, MANPI 1699765776
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,130 of the $181,461 with a category attached, or 76.1%. Actelion Pharmaceuticals US, Inc. accounts for 62.4% of it on its own, with 35 other manufacturers making up the rest. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $248.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$113K
- Bayer$53K
- GSK$6K
- Merck$5K
- AstraZeneca$1K
- Boehringer Ingelheim$455
- plus $3K from 30 others
What the payments were for
- Consulting fees$13,3657%
- Speaking & faculty fees$138,13076%
- Travel & lodging$13,9658%
- Food & beverage$15,8509%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 316 | $113,150 |
| Bayer | 72 | $53,201 |
| GSK | 141 | $5,751 |
| Merck | 13 | $5,179 |
| AstraZeneca | 48 | $1,011 |
| Boehringer Ingelheim | 20 | $455 |
| United Therapeutics Corporation | 12 | $352 |
| Sanofi | 12 | $328 |
| Verona Pharma, Inc. | 6 | $174 |
| Amgen | 6 | $156 |
| Johnson & Johnson(2 entities) | 9 | $126 |
| Viiv Healthcare Company | 6 | $122 |
| Inogen, Inc. | 6 | $112 |
| Philips North America LLC | 4 | $101 |
| Lilly USA, LLC | 4 | $94 |
| Grifols USA, LLC | 3 | $89 |
| Electromed, Inc. | 6 | $89 |
| Baxter Healthcare | 4 | $88 |
| Mylan Specialty L.p. | 4 | $81 |
| Novartis | 4 | $72 |
| Novo Nordisk | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Inspire Medical Systems, Inc. | 2 | $63 |
| Insmed, Inc. | 2 | $62 |
| Genentech USA, Inc. | 3 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| Pulmonx Corporation | 1 | $57 |
| Pfizer | 3 | $50 |
| Exact Sciences | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Covis Pharma GmbH | 2 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Phadia US Inc. | 1 | $20 |
| Circassia Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$102,056
- OPSUMIT$98,196
- Adempas$51,906
- TRELEGY ELLIPTA$3,600
- Kerendia$3,135
How this compares
$181,461 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 68 | $1,306,221 |
| OpsumitMacitentan | 78 | $990,063 |
| AdempasRiociguat | 56 | $767,953 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 173 | $134,366 |
| Ambrisentan | 12 | $24,909 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $12,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,161 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,830 |
| Cefpodoxime Proxetil | 40 | $2,732 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,506 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,685 |
| Tadalafil | 13 | $895 |
| Atorvastatin Calcium | 52 | $802 |
| Fluticasone Propionate | 50 | $480 |
| Potassium Chloride | 46 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $113,150 | $2,296,284146 claims |
| BayerAdempas | $53,201 | $767,95356 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $5,751 | $151,756208 claims |
| AstraZenecaBreztri Aerosphere | $1,011 | $10,16114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Westborough
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
- Elliot IsraelBrookline$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.